ClinicalTrials.gg
RecruitingNCT07844083IASEAMPUpdated Sep 28, 2026

Artificial Intelligence in Embryo Selection in Assisted Reproduction for Embryos Cultured to the Fifth Day of Development

An interventional study of EMA in Infertility, sponsored by University Hospital, Clermont-Ferrand. Recruiting at 1 site in France. Open to female participants aged 18 Years to 37 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled Nov 2024, registered Sep 2026).
  • Started Nov 2024; still recruiting 2 years later.
Updated Sep 28, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
550
Allocation
Randomized
Ages
18 Years to 37 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 111 studies in Infertility with a site in France — 24 open to participants now, 30 under way, 1 of them phase 3. Infertility · France.

Planned enrollment
7th of 60
550 · median 160
Started
2024
with 6 others
No phase
39 of 111
11 open now
Primary completion
2026-11
later than 15 of 29 live
Registered
110th of 111
by date
Lead sponsor
4 of 111
University Hospital, Clermont-Ferrand

Among the 111 studies in Infertility with a site in France, this one is the 7th largest by planned enrollment of the 60 interventional ones that give a count, is one of 7 that started in 2024, is one of 39 with no phase, reaches primary completion later than 15 of the 29 other live ones, and was the 110th registered.

Infertility

2,088 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

24 of the 111 studies in Infertility with a site in France are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 37 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Infertility with a site in France, or all of them as a file.
02

Study summary

Embryo selection is one of the major challenges in Assisted Reproductive Technology (ART) in order to continuously improve clinical pregnancy rates. Morphological evaluation of embryos is the standard method used to assess embryo quality and to select the embryo to be transferred. However, this observational method has limitations: it can be subjective and may lead to inter- and intra-observer variability. To increase pregnancy rates, the transfer of two embryos may be proposed, which can result in high-risk multiple pregnancies. Despite the introduction of time-lapse systems and embryo selection algorithms aimed at increasing live birth rates, outcomes in ART remain suboptimal and can still be improved.

The use of artificial intelligence (AI) is expanding in the medical field and is increasingly being applied in ART laboratories to optimize outcomes while avoiding multiple pregnancies. EMA™ is a secure artificial intelligence software platform developed by the company AiVF. The use of this software could allow a standardized and reproducible evaluation of embryo development up to the fifth day of embryonic culture. Through the application of an algorithm, the software may enable the selection of the embryo with the highest potential for achieving pregnancy.

The primary objective of this study is to evaluate the use of the EMA™ artificial intelligence system in embryo selection for embryos cultured up to day 5, in comparison with the morphokinetic criteria currently used in the laboratory for the first fresh transfer of a day-5 embryo.

The secondary objectives are to assess whether artificial intelligence (1) reduces the time to achieve pregnancy (defined as pregnancy achieved or not after the first transfer of a day-5 embryo) and (2) affects the miscarriage rate among patients treated in the ART CECOS unit. A medico-economic analysis will be conducted to evaluate the number of new patients undergoing an additional treatment attempt and to determine whether there is a correlated reduction in time to pregnancy by assessing the number of pregnancies achieved after the first transfer in patients already under treatment. A cost-effectiveness analysis will also be performed, comparing the cost-effectiveness ratios between the two study arms.

03

Conditions studied

  • Infertility

Browse trials for

Keywords

  • Artificial intelligence
  • Embryo selection
  • IVF outcome
  • Time-lapse monitoring
04

Who can participate

Ages eligible
18 Years to 37 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • First attempt at assisted reproductive technology (ART) treatment using in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI)
  • Treatment for primary infertility of idiopathic or male origin, for single women or female couples
  • Use of fresh sperm from the partner or frozen donor sperm
  • Embryo culture up to the 105th hour of development (the time at which the score is assigned when selecting the embryo to be transferred to the uterus on the 5th day of development (D5))
  • First transfer of a fresh embryo on the 5th day of culture
  • Known Implantation Data (KID) (= clinical pregnancy confirmed by the presence of a heartbeat at 6 weeks via ultrasound)

Exclusion criteria

Exclusion Criteria:

  • Use of frozen sperm from the spouse
  • No oocytes retrieved during oocyte retrieval
  • No blastocysts obtained on the 5th day of development
  • Embryo culture with transfer on the 2nd or 3rd day of development
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
550 participants (estimated)

Study arms

  • No intervention
    Manual procedure

    The embryo to be transferred on day 5 is selected by the biologist.

  • Experimental
    Artificial intelligence

    The embryo to be transferred on day 5 is selected by the artificial intelligence software

    Device: EMA

Interventions

  • DeviceEMA

    Embryo selection on the 5th day of culture is performed using artificial intelligence

06

What researchers measure

Primary outcomes

  1. Comparison of artificial intelligence (AI) Score and Laboratory Embryo Classification

    To evaluate the use of EMA artificial intelligence in embryo selection for embryos cultured through day 5, in comparison with the morphokinetic criteria (gardner classification) used in the laboratory for the first fresh transfer of an embryo cultured through day 5 of development. Gardner classification : The three blastocyst parameters will be assessed independently: the degree of blastocyst expansion, the quality of the inner cell mass, and the quality of the trophectoderm. These three parameters will then be pooled to generate an overall blastocyst classification.

    Time frame: 5 days

Secondary outcomes

  1. Impact of AI on time to obtain a pregnancy

    To assess whether artificial intelligence can reduce the time to clinical pregnancy (whether or not pregnancy is achieved after the first embryo transfer on the 5th day of culture).

    Time frame: up to 6 weeks

  2. Impact of AI on miscarriage rates

    To assess whether artificial intelligence can impact the miscarriage rate among patients treated at the AMP-CECOS clinic.

    Time frame: up to 6 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Nov 2026, 23 months after the start.

Of 386 non-industry interventional studies with no phase under Infertility, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 23 months is close to that.

Counting every sponsor, half of 416 studies reached it within 24 months; a quarter within 10 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2026
First posted
Sep 28, 2026
StartActual
Nov 4, 2024
Primary completionEst.
Nov 1, 2026
CompletionEst.
Nov 1, 2027
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07844083
Responsible party
Sponsor
First posted
Sep 28, 2026
Start date
Nov 4, 2024
Primary completion
Nov 1, 2026 (estimated)
Completion
Nov 1, 2027 (estimated)
Last update
Sep 28, 2026

Study contacts

Lise Laclautre
Contact
promo_interne_drci@chu-clermontferrand.fr
334.73.754.963
Laure Chaput, PharmD, PhD
principal investigator · ART unit

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion